The Current Role of Haematopoietic Stem Cell Transplantation in the Treatment of Lymphomas – Review

Czech version

Authors: V. Válková ¹; M. Trněný ^1,2
Authors‘ workplace: Ústav hematologie a krevní transfuze, Ústav klinické a experimentální hematologie, 1. LF UK, Praha ¹; I. interní klinika Všeobecné fakultní nemocnice, Praha ²
Published in: Klin Onkol 2010; 23(3): 155-164
Category: Reviews

Overview

Despite the undeniable progress in first‑line treatment, a significant proportion of patients with lymphoproliferative disease still relapse. Transplant strategy is one of the most effective options for such patients. Autologous stem cell transplantation has for many years been the standard position in the treatment of chemosensitive relapse of diffuse large B cell lymphoma, Hodgkin‘s lymphoma and follicular lymphoma. Recently, autologous stem cell transplantation has had significant importance in first‑line therapy of some T‑ cell lymphoma and mantle cell lymphoma as well. It is possible that this situation will change after the evaluation of clinical protocols using rituximab, either in first or second‑line therapy or as part of the conditioning regimen and maintenance therapy. In recent years, there has also been a significant shift to the use of allogeneic transplantation, particularly through the introduction of so‑ called reduced intensity (RIC‑ alo). Many studies have demonstrated a significant reduction in mortality using RIC‑ alo, while preserving the GVL effect. In recent years, significant attention has also been focused on the identification of prognostic factors that could lead to earlier intensive therapy, including RIC‑ alo, particularly in mantle cell lymphoma, some T‑ cell lymphoma and Hodgkin‘s lymphoma. However, relapses remain a major problem of treatment failure and more accurate identification of patients suitable for early transplant strategy will be required.

Key words:
lymphoma – transplantation – risk factors – relapse – mortality

Sources

1. Gratwohl A, Baldomero H, Frauendorfer K et al. Joint Accreditation Committee of the International Society for Cellular Therapy ISCT; European Group for Blood and Marrow Transplantation EBMT. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant 2007; 39(2): 71– 87.

2. Williams CD, Goldstone AH, Pearce RM et al. Purging of bone marrow in autologous bone marrow transplantation for non‑Hodgkin‘s lymphoma: a case‑ matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 1996; 14(9): 2454– 2464.

3. van Heeckeren WJ, Vollweiler J, Fu P et al. Randomised comparison of two B‑ cell purging protocols for patients with B‑ cell non‑Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device. Br J Haematol 2006; 132(1): 42– 55.

4. Vose JM, Bierman PJ, Enke C et al. Phase I trial of iodine‑ 131 tositumomab with high‑dose chemotherapy and autologous stem‑ cell transplantation for relapsed non‑Hodgkin‘s lymphoma. J Clin Oncol 2005; 23(3): 461– 467.

5. Krishnan A, Nademanee A, Fung HC et al. Phase II trial of a transplantation regimen of yttrium‑ 90 ibritumomab tiuxetan and high‑dose chemotherapy in patients with non‑Hodgkin‘s lymphoma. J Clin Oncol 2008; 26(1): 90– 95.

6. Yakoub‑ Agha I, Mesnil F, Kuentz M et al. Allogeneic marrow stem‑ cell transplantation from human leukocyte antigen‑ identical siblings versus human leukocyte antigen‑ allelic‑ matched unrelated donors (10/ 10) in patients with standard‑ risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006; 24(36): 5695– 5702.

7. Avivi I, Montoto S, Canals C et al. Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol 2009; 147(5): 719– 728.

8. Pfreundschuh M, Trümper L, Osterborg A et al. CHOP‑like chemotherapy plus rituximab versus CHOP‑like chemotherapy alone in young patients with good‑ prognosis diffuse large‑ B‑ cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7(5): 379– 391.

9. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high‑dose therapy in poor‑ risk aggressive non‑Hodgkin’s lymphoma: final analysis of the prospective LNH87– 2 protocol: a groupe d’Etude des lym‑ phomes de l’Adulte study. J Clin Oncol 2000; 18(16): 3025– 3030.

10. Gianni AM, Bregni M, Siena S et al. High‑dose chemotherapy and autologous bone marrow transplantation compared with MACOP‑ B in aggressive B‑ cell lymphoma. N Engl J Med 1997; 336(18): 1290– 1297.

11. Santini G, Salvagno L, Leoni P et al. VACOP‑ B versus VACOP‑ B plus autologous bone marrow transplantation for advanced diffuse non‑Hodgkin‘s lymphoma: results of a prospective randomized trial by the non‑Hodgkin‘s Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16(8): 2796– 2802.

12. Milpied N, Deconinck E, Gaillard F et al. Initial treatment of aggressive lymphoma with high‑dose chemotherapy and autologous stem‑ cell support. N Engl J Med 2004; 350(13): 1287– 1295.

13. Betticher DC, Martinelli G, Radford JA et al. Sequential high dose chemotherapy as initial treatment for aggressive sub‑types of non‑Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol 2006; 17(10): 1546– 1552.

14. Kluin‑Nelemans HC, Zagonel V, Anastasopoulou A et al. Standard chemotherapy with or without high‑dose chemotherapy for aggressive non‑Hodgkin‘s lymphoma: randomized phase III EORTC study. J Natl Cancer Inst 2001; 93(1): 22– 30.

15. Kaiser U, Uebelacker I, Abel U et al. Randomized study to evaluate the use of high‑dose therapy as part of primary treatment for „aggressive“ lymphoma. J Clin Oncol 2002; 20(22): 4413– 4419.

16. Mounier N, Gisselbrecht C, Brière J et al. Groupe d‘Etude des Lymphomes de l‘Adulte. Prognostic factors in patients with aggressive non‑Hodgkin‘s lymphoma treated by front‑line autotransplantation after complete remission: a cohort study by the Groupe d‘Etude des Lymphomes de l‘Adulte. J Clin Oncol 2004; 22(14): 2826– 2834.

17. Greb A, Bohlius J, Trelle S et al. High‑dose chemotherapy with autologous stem cell support in first‑line treatment of aggressive non‑Hodgkin lymphoma – results of a comprehensive meta‑analysis. Cancer Treat Rev 2007; 33(4): 338– 346.

18. Sehn LH, Berry B, Chhanabhai M et al. The revised International Prognostic Index (R‑ IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B‑ cell lymphoma treated with R‑ CHOP. Blood 2007; 109(5): 1857– 1861.

19. Vitolo U, Chiappella A, Angelucci E et al. Gruppo Italiano Multiregionale Linfomi e Leucemie (GIMURELL). Dose‑dense and high‑dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B‑ cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica 2009; 94(9): 1250– 1258.

20. Tmrneny M, Pytlik R, Belada D et al.Treatment of Diffuse Large B‑ Cell Lymphoma with Rituximab, Intensive Induction and High‑Dose Consolidation: The Final Analysis of the Czech Lymphoma Study Group (CLSG) R‑ MegaCHOP‑ ESHAP‑ BEAM (R‑ MEB) Trial. Blood 2007; 110(11): 14A.

21. Haioun C, Mounier N, Emile JF et al. Rituximab versus observation after high‑dose consolidative first‑line chemotherapy with autologous stem‑ cell transplantation in patients with poor‑ risk diffuse large B‑ cell lymphoma. Ann Oncol 2009; 20(12): 1985– 1992.

22. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy‑ sensitive non‑Hodgkin‘s lymphoma. N Engl J Med 1995; 333(23): 1540– 1545.

23. Vellenga E, van Putten WL, van ‚t Veer MB et al. Rituximab improves the treatment results of DHAP‑ VIM‑ DHAP and ASCT in relapsed/ progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008; 111(2): 537– 543.

24. Kewalramani T, Zelenetz AD, Nimer SD et al. Rituximab and ICE as second‑line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B‑ cell lymphoma. Blood 2004; 103(10): 3684– 3688.

25. Gisselbrecht C et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J Clin Oncol 2009; 27: 15 (suppl; abstr 8509).

26. Coiffier B. Effective immunochemotherapy for aggressive non‑Hodgkin‘s lymphoma. Semin Oncol 2004; 31 (1 Suppl 2): 7– 11.

27. Rodríguez J, Caballero MD, Gutiérrez A et al. Autologous stem‑ cell transplantation in diffuse large B‑ cell non‑Hodgkin‘s lymphoma not achieving complete response after induction chemotherapy: the GEL/ TAMO experience. Ann Oncol 2004; 15(10): 1504– 1509.

28. Kewalramani T, Zelenetz AD, Hedrick EE et al. High dose chemo‑ radiotherapy and autologous stem cell transplantation for patiens with primary refractory aggressive non‑Hodgkin lymphoma: an intention‑ to‑ treat analysis. Blood 2000; 96: 2399– 2404.

29. Haioun C, Itti E, Rahmouni A et al. [18F]fluoro‑2-deoxy‑ D‑ glucose positron emission tomography (FDG‑ PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106(4): 1376– 1381.

30. Chopra R, Goldstone AH, Pearce R et al. Autologous versus allogeneic bone marrow transplantation for non‑Hodgkin‘s lymphoma: a case‑ controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 1992; 10(11): 1690– 1695.

31. Peniket AJ, Ruiz de Elvira MC et al. European Bone Marrow Transplantation (EBMT) Lymphoma Registry. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure‑related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31(8): 667– 678.

32. A clinical evaluation of the International Lymphoma Study Group classification of non‑Hodgkin‘s lymphoma. The Non‑ Hodgkin‘s Lymphoma Classification Project. Blood 1997; 89(11): 3909– 3918.

33. Robinson SP, Goldstone AH, Mackinnon S et al. Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced‑ intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100(13): 4310– 4316.

34. Morris E, Thomson K, Craddock C et al. Outcomes after alemtuzumab‑ containing reduced‑ intensity allogeneic transplantation regimen for relapsed and refractory non‑Hodgkin lymphoma. Blood 2004; 104(13): 3865– 3871.

35. Armand P, Kim HT, Ho VT et al. Allogeneic transplantation with reduced‑ intensity conditioning for Hodgkin and non‑Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008; 14(4): 418– 425.

36. Sirvent A, Dhedin N, Michallet M et al. Low non‑relapse mortality and prolonged long‑term survival after reduced‑ intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B‑ cell lymphoma: Report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Biol Blood Marrow Transplant 2010; 16(1): 78– 85.

37. Thomson KJ, Morris EC, Bloor A et al. Favorable long‑term survival after reduced‑ intensity allogeneic transplantation for multiple‑relapse aggressive non‑Hodgkin‘s lymphoma. J Clin Oncol 2009; 27(3): 426– 432.

38. Hamadani M, Benson DM Jr, Hofmeister CC et al. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non‑hodgkin lymphomas. Biol Blood Marrow Transplant 2009; 15(5): 547– 553.

39. Gutman JA, Bearman SI, Nieto Y et al. Autologous transplantation followed closely by reduced‑ intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: a feasibility study. Bone Marrow Transplant 2005; 36(5): 443– 451.

40. Buser AS, Stern M, Bucher C et al. High‑dose chemotherapy using BEAM without autologous rescue followed by reduced‑ intensity conditioning allogeneic stem‑ cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation. Bone Marrow Transplant 2007; 39(6): 335– 340.

41. Savage KJ, Harris NL, Vose JM et al. International Peripheral T‑ Cell Lymphoma Project. ALK‑ anaplastic large‑ cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T‑ cell lymphoma, not otherwise specified: report from the International Peripheral T‑ Cell Lymphoma Project. Blood 2008; 111(12): 5496– 5504.

42. Blystad AK, Enblad G, Kvaløy S et al. High‑dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001; 27(7): 711– 716.

43. Song KW, Mollee P, Keating A et al. Autologous stem cell transplant for relapsed and refractory peripheral T‑ cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003; 120(6): 978– 985.

44. Kewalramani T, Zelenetz AD, Teruya‑ Feldstein J et al. Autolgous transplantation for relapsed or primary refractory peripheral T‑ cell lymphoma. Br J Haematol 2006; 134(2): 202– 207.

45. Rodríguez J, Conde E, Gutiérrez A et al. Grupo Español de Linfomas/ Trasplante Autólogo de Médula Osea, Spanish Lymphoma/ Autologous Bone Marrow Transplant Study Group. The adjusted International Prognostic Index and beta‑2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/ refractory peripheral T‑ cell lymphoma. Haematologica 2007; 92(8): 1067– 1074.

46. Reimer P, Rüdiger T, Geissinger E et al. Autologous stem‑ cell transplantation as first‑line therapy in peripheral T‑ cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009; 27(1): 106– 113.

47. Corradini P, Tarella C, Zallio F et al. Long‑term follow‑up of patients with peripheral T‑ cell lymphomas treated up‑ front with high‑dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006; 20(9): 1533– 1538.

48. Mercadal S, Briones J, Xicoy B et al. Grup per l‘Estudi dels Limfomes de Catalunya I Balears (GELCAB). Intensive chemotherapy (high‑dose CHOP/ ESHAP regimen) followed by autologous stem‑ cell transplantation in previously untreated patients with peripheral T‑ cell lymphoma. Ann Oncol 2008; 19(5): 958– 963.

49. Rodríguez J, Conde E, Gutiérrez A et al. Frontline autologous stem cell transplantation in high‑risk peripheral T‑ cell lymphoma: a prospective study from the Gel‑ Tamo Study Group. Eur J Haematol 2007; 79(1): 32– 38.

50. Corradini P, Dodero A, Zallio F et al. Graft‑ versus‑lymphoma effect in relapsed peripheral T‑ cell non‑Hodgkin‘s lymphomas after reduced‑ intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22(11): 2172– 2176.

51. Le Gouill S, Milpied N, Buzyn A et al. Société Française de Greffe de Moëlle et de Thérapie Cellulaire. Graft‑ versus‑lymphoma effect for aggressive T‑ cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol 2008; 26(14): 2264– 2271.

52. Valkova V, Benesova K, Vitek A et al. The results of allogeneic transplants in patients with malignant lymphoma‑ a retrospective analysis of data from the Czech National Registry; Neoplasma 2009; 56(1): 76– 83.

53. Goldstone AH, Richards SM, Lazarus HM et al. In adults with standard‑ risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/ maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ ECOG E2993). Blood 2008; 111(4): 1827– 1833.

54. van Imhoff GW, van der Holt B, Mackenzie MA et al. Impact of three courses of intensified CHOP prior to high‑dose sequential therapy followed by autologous stem‑ cell transplantation as first‑line treatment in poor‑ risk, aggressive non‑hodgkin‘s lymphoma: comparative analysis of Dutch‑ Belgian Hemato‑ Oncology Cooperative Group Studies 27 and 40. Dutch‑ Belgian Hemato‑ Oncology Cooperative Group. J Clin Oncol 2005; 23(16): 3793– 3801.

55. Sweetenham JW, Santini G, Qian W et al. High‑dose therapy and autologous stem‑ cell transplantation versus conventional‑dose consolidation/ maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 2001; 19(11): 2927– 2936.

56. Lenz G, Dreyling M, Schiegnitz E et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression‑free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low‑ Grade Lymphoma Study Group. Blood 2004; 104(9): 2667– 2674.

57. Deconinck E, Foussard C, Milpied N et al. GOELAMS. High‑dose therapy followed by autologous purged stem‑ cell transplantation and doxorubicin‑based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 2005; 105(10): 3817– 3823.

58. Sebban C, Mounier N, Brousse N et al. Standard chemotherapy with interferon compared with CHOP followed by high‑dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF‑ 94 randomized study from the Groupe d‘Etude des Lymphomes de l‘Adulte (GELA). Blood 2006; 108(8): 2540– 2544.

59. Ladetto M, De Marco F, Benedetti F et al. Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL). Prospective, multicenter randomized GITMO/ IIL trial comparing intensive (R‑ HDS) versus conventional (CHOP‑ R) chemoimmunotherapy in high‑risk follicular lymphoma at diagnosis: the superior disease control of R‑ HDS does not translate into an overall survival advantage. Blood 2008; 111(8): 4004– 4013.

60. Schouten HC, Qian W, Kvaloy S et al. High‑dose therapy improves progression‑free survival and survival in relapsed follicular non‑Hodgkin‘s lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21(21): 3918– 3927.

61. Sabloff M, Atkins HL, Bence‑ Bruckler I et al. A 15‑year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 2007; 13(8): 956– 964.

62. Montoto S, Canals C, Rohatiner AZ et al. Long‑term follow‑up of high‑dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. EBMT Lymphoma Working Party. Leukemia 2007; 21(11): 2324– 2331.

63. van Oers MH, Klasa R, Marcus RE et al. Rituximab maintenance improves clinical outcome of relapsed/ resistant follicular non‑Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108(10): 3295– 3301.

64. Vose JM, Bierman PJ, Loberiza FR et al. Long‑term outcomes of autologous stem cell transplantation for follicular non‑Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant 2008; 14(1): 36– 42.

65. Gopal AK, Gooley TA, Maloney DG et al. High‑dose radioimmunotherapy versus conventional high‑dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non‑Hodgkin lymphoma: a multivariable cohort analysis. Blood 2003; 102(7): 2351– 2357.

66. van Besien K, Loberiza FR Jr, Bajorunaite R et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102(10): 3521– 3529.

67. Ingram W, Devereux S, Das‑ Gupta EP et al. Outcome of BEAM‑ autologous and BEAM‑ alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol 2008; 141(2): 235– 243.

68. Khouri IF, Saliba RM, Giralt SA et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft‑ versus‑ host disease, and treatment‑related mortality. Blood 2001; 98(13): 3595– 3599.

69. Morris E, Thomson K, Craddock C et al. Outcomes after alemtuzumab‑ containing reduced‑ intensity allogeneic transplantation regimen for relapsed and refractory non‑Hodgkin lymphoma. Blood 2004; 104(13): 3865– 3871.

70. Khouri IF, McLaughlin P, Saliba RM et al. Eight‑year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111(12): 5530– 5536.

71. Vigouroux S, Michallet M, Porcher R et al. French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM‑ TC). Long‑term outcomes after reduced‑ intensity conditioning allogeneic stem cell transplantation for low‑ grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM‑ TC). Haematologica 2007; 92(5): 627– 634.

72. Hari P, Carreras J, Zhang MJ et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced‑ intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008; 14(2): 236– 245.

73. Bosch F, López‑ Guillermo A, Campo E et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998; 82(3): 567– 575.

74. Khouri IF, Romaguera J, Kantarjian H et al. Hyper‑CVAD and high‑dose methotrexate/ cytarabine followed by stem cell transplantation: an aktive regimen for aggressive mantle‑ cell lymphoma. J Clin Oncol 1998; 16(12): 3803– 3809.

75. Lefrère F, Delmer A, Suzan F et al. Sequential chemotherapy by CHOP and DHAP regiment followed by high‑ dose therapy with stem cell transplantation induces a high rate of komplete response and improves event‑free survival in mantle cell lymphoma: a prospective study. Leukemia 2002; 16(4): 587– 593.

76. Dreyling M, Lenz G, Hoster E et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression‑free survival in mantle‑ cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105(7): 2677– 2684.

77. Geisler CH, Kolstad A, Laurell A et al. Nordic Lymphoma Group. Long‑term progression‑free survival of mantle cell lymphoma after intensive front‑line immunochemotherapy with in vivo‑ purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112(7): 2687– 2689.

78. Gopal AK, Rajendran JG, Petersdorf SH et al. High‑dose chemo‑ radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99(9): 3158– 3162.

79. Khouri IF, Lee MS, Saliba RM et al. Nonablative allogeneic stem‑ cell transplantation for advanced/ recurrent mantle‑ cell lymphoma. J Clin Oncol 2003; 21(23): 4407– 4412.

80. Maris MB, Sandmaier BM, Storer BE et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004; 104(12): 3535– 3542.

81. Tam CS, Bassett R, Ledesma C et al. Mature results of the M. D. Anderson Cancer Center risk‑adapted transplantation strategy in mantle cell lymphoma. Blood 2009; 113(18): 4144– 4152.

82. Diehl V, Franklin J, Pfreundschuh M et al. German Hodgkin‘s Lymphoma Study Group. Standard and increased‑dose BEACOPP chemotherapy compared with COPP‑ ABVD for advanced Hodgkin‘s disease. N Engl J Med 2003; 348(24): 2386– 2395.

83. Bierman PJ, Sweetenham JW, Loberiza FR Jr et al. Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Syngeneic hematopoietic stem‑ cell transplantation for non‑Hodgkin‘s lymphoma: a comparison with allogeneic and autologous transplantation – The Lymphoma Working Committee of the International Bone Marrow Transplant J Clin Oncol 2003; 21(20): 3744– 3753.

84. Reece DE, Barnett MJ, Shepherd JD et al. High‑dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16– 213) with or without cisplatin (CBV +/ – P) and autologous transplantation for patients with Hodgkin‘s disease who fail to enter a complete remission after combination chemotherapy. Blood 1995; 86(2): 451– 456.

85. Horning SJ, Chao NJ, Negrin RS et al. High‑dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin‘s disease: analysis of the Stanford University results and prognostic indices. Blood 1997; 89(3): 801– 813.

86. Sureda A, Constans M, Iriondo A et al. Grupo Español de Linfomas/ Trasplante Autólogo de Médula Osea Cooperative Group. Prognostic factors affecting long‑term outcome after stem cell transplantation in Hodgkin‘s lymphoma autografted after a first relapse. Ann Oncol 2005; 16(4): 625– 633.

87. Josting A, Franklin J, May M et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin‘s lymphoma registered in the database of the German Hodgkin‘s lymphoma study group. J Clin Oncol 2002; 20(1): 221– 230.

88. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone‑ marrow transplantation in relapsed and resistant Hodgkin‘s disease: results of a BNLI randomised trial. Lancet 1993; 341(8852): 1051– 1054.

89. Schmitz N, Pfistner B, Sextro M et al. German Hodgkin‘s Lymphoma Study Group; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Aggressive conventional chemotherapy compared with high‑dose chemotherapy with autologous haemopoietic stem‑ cell transplantation for relapsed chemosensitive Hodgkin‘s disease: a randomised trial. Lancet 2002; 359(9323): 2065– 2071.

90. Constans M, Sureda A, Terol MJ et al. Autologous stem cell transplantation for primary refractory Hodgkin‘s disease: results and clinical variables affecting outcome. Ann Oncol 2003; 14(5): 745– 751.

91. Moskowitz CH, Kewalramani T, Nimer SD et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy‑ proven primary refractory Hodgkin‘s disease. Br J Haematol 2004; 124(5): 645– 652.

92. Josting A, Rueffer U, Franklin J et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000; 96(4): 1280– 1286.

93. Gajewski JL, Phillips GL, Sobocinski KA et al. Bone marrow transplants from HLA‑identical siblings in advanced Hodgkin’s disease. J Clin Oncol 1996; 14(2): 572– 578.

94. Anderson JE, Litzow MR, Appelbaum FR et al. Allogeneic, syngeneic and autologous transplanation for Hodgkin’s disease: the 21‑year Seattle experience. J Clin Oncol 1993; 11(12): 2342– 2350.

95. Akpek G, Ambinder RF, Piantadosi S et al. Long term results of blood and marrow transplantation for Hodgkin’s lymphoma. J Clin Oncol 2001; 19(23): 4314– 4321.

96. Sureda A, Robinson S, Canals C et al. Reduced‑ intensity conditioning compared with conventional allogeneic stem‑ cell transplantation in relapsed or refractory Hodgkin‘s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26(3): 455– 462.

97. Robinson SP, Sureda A, Canals C et al. Lymphoma Working Party of the EBMT. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin‘s lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009; 94(2): 230– 238.

98. Anderlini P, Saliba R, Acholonu S et al. Fludarabine‑ melphalan as a preparative regimen for reduced‑ intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin‘s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008; 93(2): 257– 264.

99. Peggs KS, Hunter A, Chopra R et al. Clinical evidence of a graft‑ versus‑ Hodgkin‘s‑lymphoma effect after reduced‑ intensity allogeneic transplantation. Lancet 2005; 365(9475): 1934– 1941.

100. Thomson KJ, Peggs KS, Smith P et al. Improved outcome following reduced intensity allogeneic transplantation in Hodgkin’s lymphoma relapsing post‑autologous transplantation. Bone Marrow Transplant 2008; 41(9): 765– 770.

101. Burroughs LM, Maris MB, Sandmaier BM et al. HLA‑matched related or unrelated donor nonmyeloablative conditioning and hematopoietic cell transplant for patients with advanced Hodgkin’s lymphoma. Biol Blood Marrow Transplant 2004: 10: 73.

102. Ljungman P, Bregni M, Brune M et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45(2): 219– 234.

Labels

Paediatric clinical oncology Surgery Clinical oncology

The Role of Permanent Brachytherapy in the Treatment of Localized Prostate Carcinoma

Staging of Non‑ Hodgkin’s Lymphoma – Recommendations of the Czech Lymphoma Study Group

Impact of Oncological Treatment on Human Reproduction

Analysis of Serum Levels of Selected Biological Parameters in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma

What is the Clinically Appropriate Approach to a Terminally Ill Oncological Patient?

Hepatocellular Carcinoma Clinical Register

Course and Conclusions of the Interdisciplinary Meeting „Winter GLIO TRACK Meeting“ 2010

Article was published in

Clinical Oncology

2010 Issue 3